Studies point that APOE4 carriers would show a more intense innate immune response that would lead to more severe systemic inflammation during the Acute Respiratory Distress Syndrome (ARDS) in SARS-CoV-2-infected patients (25). This evidence concerns the gene APOE and acute respiratory distress syndrome.